ART-123; Placebo
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01598831/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 816 чел. во всех странах исследования.
- Центров в реестре: 12 в 7 городах. Список — ниже на странице.
- Плановая дата окончания (02.2019) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 27
Критерии включения
- Subject must be receiving treatment in an ICU, or in an acute care setting (e.g., ER, RR)
- Clinical objective evidence of bacterial infection and a known site of infection.
- Cardiovascular dysfunction or Respiratory Failure due to sepsis.
- Coagulopathy characterized by an INR >1.40 without other known causes.
Критерии невключения
- Subject or Authorized Representative is unable to provide informed consent.
- Subject is pregnant or breastfeeding or intends to get pregnant within 28 days of enrolling into the study.
- Subject is of childbearing potential and does not have a negative pregnancy test.
- Subject is < 18 years of age.
- Subject has a known allergy to ART-123 or any components of the drug product.
- Subject is unwilling to allow transfusion of blood or blood products.
- Subject has an advance directive to withhold life-sustaining treatment.
- Subject has had previous treatment with ART-123.
- Body weight ≥ 175 kg.
- Platelets < 30,000/ mm3 for any reason, PT prolongation or thrombocytopenia that is not due to sepsis.
- Any surgery that is potentially hemorrhagic (e.g. intra-thoracic, intra-abdominal or non-traumatic orthopedic surgery of the femur or pelvis) that is completed within 12 hours prior to first dose of study drug, or ongoing impairment of hemostasis as a result of one of these procedures
- History of head trauma, spinal trauma, or other acute trauma with an increased risk of bleeding within 3 months prior to consent.
- Cerebral Vascular Accident (CVA) within 3 months prior to consent.
- Any history of intracerebral arteriovenous malformation (AVM), cerebral aneurysm, or mass lesions of the central nervous system.
- History of congenital bleeding diathesesor anatomical anomaly that predisposes to hemorrhage (e.g. hemophilia, hereditary hemorrhagic telangiectasia).
- Significant gastrointestinal bleeding within 6 weeks prior to consent.
- Subject is diagnosed with a known medical condition associated with a hypercoagulable state.
- Child-Pugh score of 10-15 (Class C)
- Portosystemic hypertension or known history of bleeding esophageal varices.
- History of solid organ, allogeneic bone marrow, or stem cell transplantation within the 6 months prior to consent.
- Acute pancreatitis where infection has not been documented by a positive blood or abdominal fluid culture or gram stain consistent with bacterial infection.
- Subjects with renal dysfunction defined as (a) Chronic renal failure requiring renal replacement therapy (RRT), or (b) Acute renal failure with onset of oliguria (urine output < 0.3 ml/kg/hr) > 48 hours prior to first dose of study drug whether receiving RRT or not
- Use of anticoagulants, antiplatelet agents, antithrombotics and thrombolytics within the 72 hours prior to first does of study drug.
- Life expectancy < 90 days.
- Current use of any chemotherapy agent likely to cause myeloablation (severe or complete depletion of bone marrow).
- Participation in another research study involving an investigational agent within 30 days prior to consent or projected study participation during the 28 days post study randomization.
- Confirmed or suspected endocarditis
Источник: ClinicalTrials.gov, NCT01598831 · запись обновлена в реестре 21 апреля 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 3
- Number of Participants With 28-Day All-cause Mortality — 28 days
- Number of Participants With On-Treatment Serious Major Bleeding Events — Through Study Day 28
Цель исследования
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
Где проходит
12 центров в 7 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01598831 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.